Welcome to the P&T Committee: Reining in Biotech Prices

Biotech companies have long enjoyed relative freedom from managed care cost containment. But one MCO executive--WellPoint's Chief Pharmacy Officer Robert Seidman--says the party is just about over. WellPoint's plans for the human growth hormone class once Sandoz' Omnitrope hits the market is one example of what biotech has to look forward to.